Literature DB >> 31127935

PTEN modulates gene transcription by redistributing genome-wide RNA polymerase II occupancy.

Ata Abbas1, Roshan Padmanabhan1, Todd Romigh1, Charis Eng1,2,3,4.   

Abstract

Control of gene expression is one of the most complex yet continuous physiological processes impacting cellular homeostasis. RNA polymerase II (Pol II) transcription is tightly regulated at promoter-proximal regions by intricate dynamic processes including Pol II pausing, release into elongation and premature termination. Pol II pausing is a phenomenon where Pol II complex pauses within 30-60 nucleotides after initiating the transcription. Negative elongation factor (NELF) and DRB sensitivity inducing factor (DSIF) contribute in the establishment of Pol II pausing, and positive transcription elongation factor b releases (P-TEFb) paused complex after phosphorylating DSIF that leads to dissociation of NELF. Pol II pausing is observed in most expressed genes across the metazoan. The precise role of Pol II pausing is not well understood; however, it's required for integration of signals for gene regulation. In the present study, we investigated the role of phosphatase and tensin homolog (PTEN) in genome-wide transcriptional regulation using PTEN overexpression and PTEN knock-down models. Here we identify that PTEN alters the expression of hundreds of genes, and its restoration establishes genome-wide Pol II promoter-proximal pausing in PTEN null cells. Furthermore, PTEN re-distributes Pol II occupancy across the genome and possibly impacts Pol II pause duration, release and elongation rate in order to enable precise gene regulation at the genome-wide scale. Our observations demonstrate an imperative role of PTEN in global transcriptional regulation that will provide a new direction to understand PTEN-associated pathologies and its management.
© The Author(s) 2019. Published by Oxford University Press.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31127935      PMCID: PMC6735678          DOI: 10.1093/hmg/ddz112

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  46 in total

1.  How slow RNA polymerase II elongation favors alternative exon skipping.

Authors:  Gwendal Dujardin; Celina Lafaille; Manuel de la Mata; Luciano E Marasco; Manuel J Muñoz; Catherine Le Jossic-Corcos; Laurent Corcos; Alberto R Kornblihtt
Journal:  Mol Cell       Date:  2014-05-01       Impact factor: 17.970

Review 2.  The multiple layers of non-genetic regulation of PTEN tumour suppressor activity.

Authors:  Nádia C Correia; Ana Gírio; Inês Antunes; Leila R Martins; João T Barata
Journal:  Eur J Cancer       Date:  2013-09-19       Impact factor: 9.162

3.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

4.  Lifetime cancer risks in individuals with germline PTEN mutations.

Authors:  Min-Han Tan; Jessica L Mester; Joanne Ngeow; Lisa A Rybicki; Mohammed S Orloff; Charis Eng
Journal:  Clin Cancer Res       Date:  2012-01-15       Impact factor: 12.531

5.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

6.  PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome.

Authors:  Xin He; Motoyasu Saji; Deepa Radhakrishnan; Todd Romigh; Joanne Ngeow; Qi Yu; Yu Wang; Matthew D Ringel; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-09-07       Impact factor: 5.958

Review 7.  Directly targeting transcriptional dysregulation in cancer.

Authors:  Thomas J Gonda; Robert G Ramsay
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

8.  RNA polymerase II pausing can be retained or acquired during activation of genes involved in the epithelial to mesenchymal transition.

Authors:  Ann Samarakkody; Ata Abbas; Adam Scheidegger; Jessica Warns; Oscar Nnoli; Bradley Jokinen; Kris Zarns; Brooke Kubat; Archana Dhasarathy; Sergei Nechaev
Journal:  Nucleic Acids Res       Date:  2015-03-27       Impact factor: 16.971

Review 9.  PTEN: Multiple Functions in Human Malignant Tumors.

Authors:  Michele Milella; Italia Falcone; Fabiana Conciatori; Ursula Cesta Incani; Anais Del Curatolo; Nicola Inzerilli; Carmen M A Nuzzo; Vanja Vaccaro; Sabrina Vari; Francesco Cognetti; Ludovica Ciuffreda
Journal:  Front Oncol       Date:  2015-02-16       Impact factor: 6.244

10.  Neural transcriptome of constitutional Pten dysfunction in mice and its relevance to human idiopathic autism spectrum disorder.

Authors:  A K Tilot; G Bebek; F Niazi; J B Altemus; T Romigh; T W Frazier; C Eng
Journal:  Mol Psychiatry       Date:  2015-03-10       Impact factor: 15.992

View more
  1 in total

1.  Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice.

Authors:  Ritika Jaini; Matthew G Loya; Alexander T King; Stetson Thacker; Nicholas B Sarn; Qi Yu; George R Stark; Charis Eng
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.